Indolent handling of the pharmaceutical industry harms the the Medical Products Agency's credibility
Mulinari, S.
Lakartidningen 109(46): 2107
2012
ISSN/ISBN: 0023-7205 PMID: 23259220 Document Number: 661796
Document emailed within 1 workday
Related Documents
Claude, J.R. 2001: Safety assessment of new products developed by the pharmaceutical industry Annales Pharmaceutiques Francaises 59(5): 324-330Zinn, W. 1973: Production and control in the pharmaceutical industry. Treatment of initial substances and materials. Requirements of the iks (intercantonal control agency) guide lines Pharmaceutica Acta Helvetiae 48(1): 1-21
De Francisco, A.L.M. 2004: Medical doctors and pharmaceutical industry Nefrologia: Publicacion Oficial de la Sociedad Espanola Nefrologia 24(5): 393-394
Rastad, J.A. 2005: The Medical Products Agency didn't "choose" Artrox Lakartidningen 102(40): 2886
Montgomery, R.G.; Demissianos, H.V.; Hagans, J.A.; Patel, N.C. 1971: The medical research assistant in the pharmaceutical industry Internationale Zeitschrift für Klinische Pharmakologie Therapie und Toxikologie. International Journal of Clinical Pharmacology Therapy and Toxicology 4(4): 404-407
Robinson, D.S. 1994: Psychotropic drug labeling: regulatory, pharmaceutical industry, and clinical issues and perspectives. a pharmaceutical industry perspective on drug labeling Psychopharmacology Bulletin 30(1): 23-25
Miyata, Y. 2010: Conflict of interest regarding clinical physicians' relationship with pharmaceutical industry and medical education Seishin Shinkeigaku Zasshi 112(11): 1136-1145
Blomgren, K.; Alván, G. 1996: New guidelines from the Medical Products Agency: the triple regime against Helicobacter pylori is necessary. Treat only if the ulcer is verified Lakartidningen 93(11): 1041-2 1045
Christensen, E.A. 1975: Sterilization methods in industry. Microbiological evaluation of sterilized medical products Acta Pharmaceutica Suecica 12 Suppl: 1-5
Beermann, Börn. 2006: Reply concerning the new Medical Products Agency's guidelines for primary prevention of cardiovascular diseases. Issuing recommendations based on available evidence basis an ethical duty Lakartidningen 103(47): 3731-3732
Bargagna Prunai, P.; Cinci, A.; Silvestri, S. 1972: Polarographic and colorimetric simultaneous automatic determination respectively of methylesculetol and rutin in pharmaceutical preparations. Checking of some pharmaceutical products. Xi Il Farmaco; Edizione Pratica 27(2): 89-102
Gerdén, B. 2005: The Medical Products Agency about SSRi to pregnant women and adverse effects on the fetus. Long-term adverse effects are not proved, documentation is insufficient, more research is necessary Lakartidningen 102(10): 791
Chaffin, D.B. 1979: Manual materials handling: the cause of over-exertion injury and illness in industry Journal of Environmental Pathology and Toxicology 2(5): 31-66
Kaiser, V. 1990: The so-called objectification and "credibility" of health disorders within the framework of medical expertise Aktuelle Traumatologie 20(2): 108-109
Andersen, K. 1975: The responsibility of the pharmaceutical industry Nordisk Medicin 90(4): 115
Schwarting, J.S. 2000: The pharmaceutical industry--to whom is it accountable? New England Journal of Medicine 343(19): 1416; Discussion 1417
Kahn, M.F. 1984: More on rheumatology and the pharmaceutical industry Journal of Rheumatology 11(5): 717-718
Walker, A.M.; García Rodríguez, L.A.; Pérez Gutthann, S. 1992: Epidemiology and the pharmaceutical industry Medicina Clinica 98(12): 465-468
Cohen, A.F. 2005: The pharmaceutical industry in uproar Nederlands Tijdschrift Voor Geneeskunde 149(19): 1074
Aumonier, J. 2003: Action of the pharmaceutical industry Annales Pharmaceutiques Francaises 61(6): 378-382